Title: Anticoagulant Drugs With or Without Proton Pump Inhibitor and Colorectal Cancer Risk:
A Population-Based, Case-Control Study
Version: 3 Date: 11 Jan 2022
Reviewer:  Isabel Portillo
Reviewer's report:
Dear authors,
It was a pleasure to review your work. However, I would like to give you some remarks:
1) How do you calculate the exposition time? Why 40 days or 84 days? I think will be useful
you explain better this issue
2) Did you consider the adherence to treatment?
3) The rate of CRC incidence and mortality  in Asia is very different between countries and
possible associated to different life styles and Health care investment. Maybe your results are
not applicable for other countries in this huge continent.
Although, your study will be useful to give a new highlight  about the PPI prescription and CRC
risk. PPI are a common drug prescribed in developped countries.
Best Regards
Title: Anticoagulant Drugs With or Without Proton Pump Inhibitor and Colorectal Cancer Risk:
A Population-Based, Case-Control Study
Version: 3 Date: 11 Jan 2022
Reviewer:  Isabel Portillo
Reviewer's report:
Dear authors,
It was a pleasure to review your work. However, I would like to give you some remarks:
1) How do you calculate the exposition time? Why 40 days or 84 days? I think will be useful
you explain better this issue
2) Did you consider the adherence to treatment?
3) The rate of CRC incidence and mortality  in Asia is very different between countries and
possible associated to different life styles and Health care investment. Maybe your results are
not applicable for other countries in this huge continent.
Although, your study will be useful to give a new highlight  about the PPI prescription and CRC
risk. PPI are a common drug prescribed in developped countries.
Best Regards
Please review this paper.
user
Title: Anticoagulant Drugs With or Without Proton Pump Inhibitor and Colorectal Cancer Risk:
A Population-Based, Case-Control Study
Version: 3 Date: 11 Jan 2022
Reviewer:  Isabel Portillo
Reviewer's report:
Dear authors,
It was a pleasure to review your work. However, I would like to give you some remarks:
1) How do you calculate the exposition time? Why 40 days or 84 days? I think will be useful
you explain better this issue
2) Did you consider the adherence to treatment?
3) The rate of CRC incidence and mortality  in Asia is very different between countries and
possible associated to different life styles and Health care investment. Maybe your results are
not applicable for other countries in this huge continent.
Although, your study will be useful to give a new highlight  about the PPI prescription and CRC
risk. PPI are a common drug prescribed in developped countries.
Best Regards
assistant